New antibody drug aims to turn immune cells against cancer

NCT ID NCT07563829

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and find the right dose for future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract neoplasm colorectal carcinoma gastric carcinoma gastroesophageal cancer metastatic malignant neoplasm Neoplasm Metastasis non-small cell lung carcinoma ovarian carcinoma pancreatic adenocarcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins

    Baltimore, Maryland, 21287, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Montefiore

    The Bronx, New York, 10461, United States

  • NEXT

    Fairfax, Virginia, 22031, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • University of California - San Diego

    La Jolla, California, 92093, United States